



Doc. No.	Rev	<b>Effective Date</b>
PI114	2	270CT2025

# Human Platelet Lysate (hPL) PLATINUM – Research Grade

# **Product Description**

Manufactured by the Belgian Red Cross Flanders, this Research Grade hPL is a growth factor-rich cell culture supplement derived from human platelet concentrates. Each batch of hPL contains material from 480 donors.

The product is fibrinogen depleted and does not contain heparin. This is a xeno-free product.

This hPL was manufactured under a quality management system based on ISO-13485. The principles, recommendations and requirements of ISO-20399 and of the European Pharmacopoeia (Chapter regarding raw materials of biological origin for the production of cell-based and gene therapy medicinal products) have been applied.

## **Product Presentation**

Product Code	Product Description	Size
HPL-602U-480	Human Platelet Lysate (hPL) PLATINUM Research Grade (480 donors)	180 mL
HPL-602C-480	Human Platelet Lysate (hPL) PLATINUM Research Grade (480 donors)	30 mL

## Instructions for use

# Storage/Stability

This product should be stored at  $\leq$  -70°C upon receipt. Thaw at room temperature or in a water bath ≤37°C. After thawing, aliquot at will and store aliquots at -20°C or colder. It is recommended to store the products at -15°C to -30°C for no more than 8 weeks. For long term storage, temperatures ≤-70°C are recommended.

Multiple freeze/thaw cycles may lead to increased turbidity and lower efficiency.

The expiry date of the product is indicated on the product label.

# **QUALITY - TRACEABILITY - INTEGRITY**

#### Life Science Production

The Science Centre, 1 Blaydon Road, Sandy, Bedfordshire, SG19 1RZ

Tel: +44 (0) 1234 889180 Email: sales@lifesciencegroup.co.uk Web: www.lifesciencegroup.co.uk















Doc. No.	Rev	<b>Effective Date</b>
PI114	2	27OCT2025

# **Preparation**

For use in cell culture media, we recommend an optimal dilution of 10% (vol/vol) in basal medium. In rare cases a concentration of hPL >10% (vol/vol) may cause salt precipitation if used in basal media containing high phosphate concentrations (e.g. RPMI) combined with certain cell types.

# **Precautions and safety**

- For Research Use only
- Not intended for therapeutic or diagnostic procedures, animals or humans.
- Not intended for direct use in animals or humans
- These products should be handled and treated as potentially infectious
- Apply GLP according to biosafety regulations.

The hPL is derived from human platelet concentrates prepared from donations collected from consenting, non-remunerated voluntary donors of the Belgian Red Cross Flanders.

The source products for production of hPL are prepared according to Belgian legislation.

The hPL production process includes a pathogen inactivation step (using the INTERCEPT method from Cerus) on the final product. This reduces the risk of transmission of HIV, HCV and HBV to almost zero. Due to it's broad spectrum of action, pathogen inactivation also significantly protects against transmission of less or unknown pathogens (emerging infections diseases). However, such transmission can never be excluded.

Prions are not eliminated by pathogen inactivation and cannot be detected in donors by routine laboratory tests. Protection against the transmission of prions by transfusion relies on careful donor selection.

Although these donor screening, testing and pathogen inactivation procedures are in place to minimise the risk of transmitting infections, they cannot completely eliminate this risk. Therefore the products should be handled and treated as potentially infectious.

# Support

To learn more, contact us by telephone at +44 1234 889180 or email at sales@lifesciencegroup.co.uk

# **QUALITY - TRACEABILITY - INTEGRITY**

#### Life Science Production

The Science Centre, 1 Blaydon Road, Sandy, Bedfordshire, SG19 1RZ

Tel: +44 (0) 1234 889180 Email: sales@lifesciencegroup.co.uk Web: www.lifesciencegroup.co.uk









